DSwiss reported fiscal 2025 revenue of $2.92 million and a net loss of $0.0769 million, producing basic and diluted loss per share of $(0.0004). Revenue declined modestly year-over-year and gross margin compressed slightly, contributing to an operating loss and a small net loss for the period.
Financial Highlights
- Revenue: $2.920986 million, decreased $0.192M (6.16%) versus prior year per MD&A.
- Gross Profit: $0.564562 million; gross margin 19.33% (down 0.69 percentage points from 20.02%).
- Operating Income: $(0.060888) million (operating loss as reported).
- Net Income: $(0.076860) million (net loss for the period; prior year net profit $22,223).
- Net (Loss)/Profit Per Share: $(0.0004) per share, basic and diluted.
Business Highlights
- Revenue Trend: Revenue declined 6.2% year-over-year to $2.92 million in 2025, reflecting softer OEM/ODM sales and a slight reduction in gross margin to 19.3%.
- Channel Strategy: The company operates exclusively online and plans an aggressive expansion of social media channels (Facebook, Instagram, WeChat) to drive direct sales growth.
- Products and Brand: Markets nutraceuticals, skincare products and a proprietary Quantum Resonant Magnetic Analyzer positioned as a differentiating health/beauty technology offering.
- Operational Expansion: Consolidated operations in Malaysia and completed an acquisition to own DSwiss Biotech Sdn Bhd (100%), positioning the company for expanded presence in Southeast Asia.
- R&D and Regulatory: Continuing R&D efforts with Malaysia Ministry of Health certifications underway; plans include product launches and building distributor partnerships across Southeast Asia.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.